Yumanity Therapeutics Inc. engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein.
Market Cap | 42.496 Million | Shares Outstanding | 9.769 Million | Avg 30-day Volume | 14.662 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 42.0588 | EPS | -1.14 |
Price to Revenue | 6.7312 | Debt to Equity | 0.2825 | EBITDA | -56.289 Million |
Price to Book Value | 14.7049 | Operating Margin | -648.7097 | Enterprise Value | 33.338 Million |
Current Ratio | 1.03 | EPS Growth | -2.218 | Quick Ratio | 0.993 |
1 Yr BETA | 1.7619 | 52-week High/Low | 9.0 / 0.29 | Profit Margin | -984.1289 |
Operating Cash Flow Growth | -281.9168 | Free Cash Flow to Firm (FCFF) TTM | -26.006 Million | Free Cash Flow to Equity (FCFE) TTM | -25.46 Million |
Altman Z-Score | -35.0558 |
Please sign in first
8 Thousand total shares from 3 transactions
none
4.4 Thousand total shares from 1 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
PHILIPS CRAIG W. PRESIDENT |
|
95,465 | 2023-11-28 | 7 |
IADONATO SHAWN CHIEF EXECUTIVE OFFICER |
|
1,354,913 | 2023-11-28 | 7 |
|
143,204 | 2023-10-11 | 4 | |
KENNY PAULINE GENERAL COUNSEL & SECRETARY |
|
18,448 | 2023-09-20 | 6 |
|
861,435 | 2023-09-19 | 7 | |
BAKER KEITH CHIEF FINANCIAL OFFICER |
|
16,880 | 2023-09-18 | 5 |
GUILLAUDEUX THIERRY CHIEF SCIENTIFIC OFFICER |
|
21,696 | 2023-09-14 | 4 |
|
0 | 2023-07-01 | 2 | |
|
0 | 2023-07-01 | 2 | |
|
0 | 2023-04-12 | 1 | |
|
0 | 2023-04-12 | 2 | |
SMITH DEVIN WHITTEMORE SVP AND GENERAL COUNSEL |
|
13,961 | 2022-12-02 | 0 |
EPSTEIN MARIE PRINCIPAL ACCOUNTING OFFICER |
|
8,883 | 2022-12-02 | 0 |
WYZGA MICHAEL D SEE REMARKS |
|
13,997 | 2022-12-02 | 0 |
MOHSEN PAULASH CHIEF BUSINESS OFFICER |
|
59,135 | 2022-02-03 | 0 |
VERMA AJAY EVP, HEAD OF R&D |
|
5,000 | 2021-11-11 | 0 |
|
14,800 | 2021-06-02 | 0 | |
|
14,800 | 2021-06-02 | 0 | |
|
14,800 | 2021-06-02 | 0 | |
|
14,800 | 2021-06-02 | 0 | |
|
14,800 | 2021-06-02 | 0 | |
COLES N ANTHONY EXECUTIVE CHAIR |
|
78,650 | 2021-04-01 | 0 |
ROBERTSON BRIGITTE CHIEF MEDICAL OFFICER |
|
0 | 2021-02-01 | 0 |
|
0 | 2020-06-29 | 0 | |
|
0 | 2020-06-29 | 0 | |
|
0 | 2020-06-29 | 0 | |
ALFIERI MICHAEL INTERIM HEAD OF FINANCE |
|
0 | 2020-05-12 | 0 |
CHHABRA MEENU PRESIDENT AND CEO |
|
0 | 2020-03-02 | 0 |
MUNOZ BENITO CHIEF SCIENTIFIC OFFICER |
|
0 | 2020-03-02 | 0 |
LARSON ERIC D SEE REMARKS |
|
0 | 2020-03-02 | 0 |
GILMARTIN GEOFFREY S. CHIEF MEDICAL OFFICER |
|
0 | 2020-03-02 | 0 |
ZECEVIC MARIJA CHIEF COMMERCIAL OFFICER |
|
0 | 2020-03-02 | 0 |
WILSON SHEILA CHIEF OPERATING OFFICER |
|
0 | 2020-03-02 | 0 |
NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP |
|
No longer subject to file | 2019-11-26 | 0 |
LEE PO SHUN SEE REMARKS |
|
0 | 2019-03-01 | 0 |
ZIMMERMAN SANDRA M. SEE REMARKS |
|
0 | 2018-08-06 | 0 |
|
0 | 2018-06-15 | 0 | |
|
0 | 2018-06-15 | 0 | |
BOUDREAU HELEN M CHIEF FINANCIAL OFFICER |
|
0 | 2018-03-01 | 0 |
CORMORANT ASSET MANAGEMENT, LLC |
|
No longer subject to file | 2017-12-14 | 0 |
HAGEN BRETT R SEE REMARKS |
|
0 | 2017-04-03 | 0 |
|
No longer subject to file | 2017-03-13 | 0 | |
NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP |
|
3,554,610 | 2016-09-14 | 0 |
DETORE JAMES M. SEE REMARKS |
|
0 | 2016-08-04 | 0 |
HEALTHCARE VENTURES VIII, L.P. |
|
2,164,095 | 2016-02-17 | 0 |
|
No longer subject to file | 2016-02-17 | 0 | |
|
2,908,067 | 2016-02-10 | 0 | |
|
6,012 | 2016-02-10 | 0 | |
THIBAULT LANCE E SEE REMARKS |
|
0 | 2016-02-10 | 0 |
|
0 | 2016-02-10 | 0 | |
|
0 | 2016-02-10 | 0 | |
MIRZAC ROMEO PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2016-02-10 | 0 |
SMART JANET L SEE REMARKS |
|
0 | 2016-02-10 | 0 |
|
0 | 2016-02-10 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-30 17:21:22 -0500 | 2023-11-29 | P | 4,100 | $3.51 | a | 675,230 | direct | 4.3902 | 4.3902 | 2 | 0.0 | 1 | ||||
2023-11-30 17:21:22 -0500 | 2023-11-28 | P | 900 | $3.33 | a | 671,130 | direct | 4.3902 | 4.3902 | 2 | 0.0 | 1 | ||||
2023-11-30 17:27:11 -0500 | 2023-11-28 | P | 3,000 | $3.27 | a | 60,811 | direct | 4.3902 | 4.3902 | 2 | 0.0 | 1 | ||||
2023-10-12 16:25:50 -0400 | 2023-10-11 | M | 4,443 | $0.14 | a | 143,204 | direct | 0.0 | 0.8287 | -14.3646 | 22.0994 | 17 | -14.3646 | 31 | ||
2023-10-12 16:25:50 -0400 | 2023-10-11 | M | 4,443 | d | 0 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
KINETA INC KA | 2023-12-06 19:45:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 19:15:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 18:45:03 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 18:15:03 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 17:45:03 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 17:15:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 16:45:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 16:15:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 15:45:03 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 15:15:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 14:45:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 14:15:04 UTC | -11.9357 | 17.2557 | 550000 |
KINETA INC KA | 2023-12-06 13:45:04 UTC | -12.2694 | 17.5894 | 550000 |
KINETA INC KA | 2023-12-06 13:15:04 UTC | -12.2694 | 17.5894 | 550000 |
KINETA INC KA | 2023-12-05 22:15:04 UTC | -12.2694 | 17.5894 | 600000 |
KINETA INC KA | 2023-12-05 21:45:04 UTC | -12.2694 | 17.5894 | 600000 |
KINETA INC KA | 2023-12-05 21:15:04 UTC | -12.2694 | 17.5894 | 600000 |
KINETA INC KA | 2023-12-05 20:45:04 UTC | -12.2694 | 17.5894 | 600000 |
KINETA INC KA | 2023-12-05 20:15:04 UTC | -12.2694 | 17.5894 | 600000 |
KINETA INC KA | 2023-12-05 19:45:04 UTC | -12.2694 | 17.5894 | 600000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|